FAQ/Help |
Calendar |
Search |
Today's Posts |
11-12-2016, 07:40 AM | #1 | ||
|
|||
News Gatherer
Community Support Team
|
Investor's Business Daily Acadia Faces Education Battle With Parkinson's Drug Investor's Business Daily Acadia Pharmaceuticals (ACAD) faces an uphill battle educating doctors on Nuplazid, its drug to treat psychosis associated with Parkinson's disease, Goldman Sachs analyst Salveen Richter said Friday as she initiated coverage with a neutral rating. Today's Rating Change: Is Goldman Sachs Positive On ACADIA Pharmaceuticals (NYSE:ACAD)?Thorold News all 20 news articles » More... |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
FDA Approves First Drug For Psychosis Linked To Parkinson's - Medical Daily | Parkinson's News |